Wiles Jason A, Wang Qiuping, Lucien Edlaine, Hashimoto Akihiro, Song Yongsheng, Cheng Jijun, Marlor Christopher W, Ou Yangsi, Podos Steven D, Thanassi Jane A, Thoma Christy L, Deshpande Milind, Pucci Michael J, Bradbury Barton J
Achillion Pharmaceuticals, Inc., 300 George Street, New Haven, CT 06511-6653, USA.
Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6. doi: 10.1016/j.bmcl.2005.11.065. Epub 2005 Dec 7.
This report describes 9H-isothiazolo[5,4-b]quinoline-3,4-diones (ITQs) containing aromatic groups at the 7-position that were prepared using palladium-catalyzed cross-coupling and tested against a panel of susceptible and resistant bacteria. In general, these compounds were more effective against Gram-positive than Gram-negative organisms. Many of the ITQs were more potent than contemporary quinolones and displayed a particularly strong antistaphylococcal activity against a clinically important, multi-drug-resistant strain. In contrast with ITQs reported previously, several of the analogues described in this Letter demonstrated low cytotoxic activity against a human cell line.
本报告描述了在7位含有芳基的9H-异噻唑并[5,4-b]喹啉-3,4-二酮(ITQ),其通过钯催化的交叉偶联反应制备,并针对一组敏感和耐药细菌进行了测试。总体而言,这些化合物对革兰氏阳性菌的效果比对革兰氏阴性菌更好。许多ITQ比当代喹诺酮类药物更有效,并且对一种临床上重要的多重耐药菌株表现出特别强的抗葡萄球菌活性。与先前报道的ITQ不同,本信函中描述的几种类似物对人细胞系显示出低细胞毒性活性。